Sara Haug, MD
Retina Specialist · Durango, CONPI 1871820837
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,340 of the $59,367 with a category attached, or 76.4%. 13 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 44.8% of the total. Reporting peaked in 2022 at $31,280 and has fallen 98.9% since, to $343 in 2025. Among retina specialist clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $534.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$27K
- Genentech USA, Inc.$23K
- Genentech, Inc.$9K
- Regeneron Healthcare Solutions, Inc.$637
- Astellas Pharma US Inc$215
- AbbVie$142
- plus $308 from 7 others
Across 431 payments — averaging $21,965 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$7.9M
- Genentech, Inc.$1.3M
- Apellis Pharmaceuticals, Inc.$190K
- AbbVie$39K
- Janssen Global Services, LLC$12K
- F. Hoffmann-la Roche AG$11K
What the payments were for
- Consulting fees$45,34076%
- Travel & lodging$10,61618%
- Food & beverage$3,4116%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 7 | $26,613 |
| Genentech USA, Inc. | 37 | $22,623 |
| Genentech, Inc. | 16 | $8,829 |
| Regeneron Healthcare Solutions, Inc. | 15 | $637 |
| Astellas Pharma US Inc | 12 | $215 |
| AbbVie(2 entities) | 10 | $142 |
| Novartis | 5 | $97 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $70 |
| Apellis Pharmaceuticals, Inc. | 2 | $44 |
| Alimera Sciences, Inc. | 2 | $41 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Eyepoint US, Inc. | 1 | $18 |
| Alcon | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,367 in reported general payments places this provider in the 90th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 205 | $7,589 |
| Latanoprost | 172 | $1,020 |
| Timolol Maleate | 89 | $777 |
| Ofloxacin | 71 | $757 |
| Brimonidine Tartrate | 33 | $318 |
| Dorzolamide Hcl | 17 | $217 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $207 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Durango
- Moss FenbergDurango$20K
- Kyle PiwonkaDurango$2K
- Murtaza AdamParker$548K
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
- Talisa ForestAurora$84K
- Matthew ManryLongmont$43K
- Ashleigh LevisonLafayette$33K
- Mimi LiuEnglewood$23K
- Lynn HassmanAurora$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.